Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:47 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

NCT02437162 · Janssen Research & Development, LLC · PHASE3 · terminated · last registry update 2025-04-29 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Neither dose achieved the study's primary or major secondary endpoints. The safety profile was consistent with previous ustekinumab studies.”	–	Registry record, Janssen Research & Development, LLC

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against IL12B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision